<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115204</url>
  </required_header>
  <id_info>
    <org_study_id>EC-Doc</org_study_id>
    <nct_id>NCT02115204</nct_id>
  </id_info>
  <brief_title>4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF</brief_title>
  <official_title>Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --&gt; 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West German Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AGO Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West German Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taxane-based adjuvant chemotherapy is standard in node-positive (N+) early breast cancer
      (BC). The magnitude of benefit in intermediate-risk N+ early BC is still unclear. West German
      Study Group and &quot;Arbeitsgemeinschaft Gynäkologische Onkologie&quot; (WSG-AGO) EC-Doc is a large
      trial evaluating modern sequential taxane-based chemotherapy in the subgroup with 1-3
      involved lymph nodes (LN).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of event-free survival</measure>
    <time_frame>60 months after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of overall survival</measure>
    <time_frame>60 months after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of toxicity (measured as number of adverse events)</measure>
    <time_frame>60 months after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of quality of life</measure>
    <time_frame>60 months after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of cost effectiveness across the applied regimens in relation to event-free survival</measure>
    <time_frame>60 months after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2011</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>EC-Doc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v., q = 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CMF/CEF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>EC-Doc</arm_group_label>
    <arm_group_label>CMF/CEF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>EC-Doc</arm_group_label>
    <arm_group_label>CMF/CEF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>EC-Doc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>CMF/CEF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <arm_group_label>CMF/CEF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients

          -  Age 18-65 years

          -  Eastern Cooperative Oncology Group (ECOG) status &lt; 2

          -  Surgery: R0-resection and &gt;= 10 removed axillary lymph nodes

          -  M0 by chest x-ray, bone scintigraphy and liver sonography

        Exclusion Criteria:

          -  Polyneuropathy

          -  Creatinin (serum) &gt; 1,4 mg/dl; Bilirubin (serum) &gt; 2,0 mg/dl

          -  Cardia dysfunction, ejection fraction &lt; lower normal value of each institution

          -  Hematopoeitic insufficiency: leucocytes &lt; 3,5 G/l, thrombocytes &lt; 100 G/l

          -  second malignant neoplasia, except curatively treated basalioma of the skin

          -  Surgery before more the six weeks (42 days)

          -  Concurrent pregnancy; patients of childbearing potential must implement a highly
             effective (less than 1% failure rate) non-hormonal contraceptive measures during the
             study treatment

          -  Breast feeding woman

          -  Sequential breast cancer

          -  Reasons indicating risk of poor compliance

          -  Patients not able to consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Nitz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ev. Hospital Bethesda, Moenchengladbach</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ev. Hospital Bethesda</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2899.</citation>
    <PMID>24827128</PMID>
  </results_reference>
  <results_reference>
    <citation>Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28.</citation>
    <PMID>25721604</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

